-
EZ Cap™ Human PTEN mRNA (ψUTP) Workflow
2026-09-03
Build more controlled PTEN restoration assays with Cap 1, pseudouridine-modified, polyadenylated mRNA. This practical guide connects delivery design, pathway-level validation, and troubleshooting for cancer research models, including trastuzumab-resistant breast cancer systems.
-
AZD1390: A Decision Framework for ATM–G4 Stress
2026-09-02
AZD1390 is a selective ATM kinase inhibitor for separating radiation-driven DNA damage from replication-associated G-quadruplex stress. This article translates REV1–DHX36 findings into practical assay decisions for cancer research, with emphasis on glioblastoma radiosensitization and mechanistic controls.
-
SU6656: A Src Inhibitor for Polyploidization
2026-09-02
Explore how SU6656, a Src tyrosine kinases inhibitor, can be evaluated in megakaryocyte polyploidization assays and preclinical cancer research. This guide distinguishes validated findings from protocol-level hypotheses and connects assay design with radiotherapy studies.
-
Cell Counting Kit-8 for MgO Implant Studies
2026-09-01
Use Cell Counting Kit-8 to quantify how MgO coating chemistry and gamma-ray treatment affect bone-forming cell survival and expansion. This workflow separates true cytotoxicity from material interference while pairing metabolic readouts with osteogenic and antibacterial endpoints.
-
KPT330 and Cas9 Precision via mRNA Export
2026-09-01
The reference study identified selective inhibitors of nuclear export, including KPT330, as indirect modulators that improve CRISPR-Cas9 and base-editing specificity by interfering with Cas9 mRNA export rather than directly blocking Cas9 protein. Its findings establish transcript trafficking as a controllable layer for genome-editing safety, while also highlighting the need to validate compound effects across editors, cell types, and delivery formats.
-
BX795: A Practical PDK1 Inhibitor Workflow
2026-08-31
BX795 supports mechanism-resolved studies of PDK1, TBK1, and IKKε across kinase, cancer-cell, and innate-immunity assays. This guide shows how to distinguish pathway inhibition from general cytotoxicity and how to pair dose responses with orthogonal readouts for more reliable conclusions.
-
3-Bromopyruvate Reverses Cetuximab Resistance
2026-08-31
The reference study shows that combining 3-bromopyruvate with cetuximab can suppress colorectal cancer cells that are intrinsically or adaptively resistant to cetuximab. Its central mechanistic contribution is the identification of FOXO3a-dependent signaling that links autophagy, ferroptosis, and apoptosis, providing a framework for dissecting combination treatment responses.
-
Lipid Peroxidation (MDA) Assay Kit Guide
2026-08-30
A scenario-based guide to selecting, running, and interpreting the Lipid Peroxidation (MDA) Assay Kit, SKU K2167, for oxidative stress and ferroptosis studies. It explains matrix compatibility, dual-mode detection, assay controls, and practical vendor-selection criteria for reproducible malondialdehyde measurement.
-
3-Deazaneplanocin (DZNep) in Epigenetic Assays
2026-08-29
3-Deazaneplanocin (DZNep) is a nanomolar epigenetic modulator for connecting SAHH inhibition with EZH2-pathway changes, apoptosis, proliferation, and tumor-initiating-cell assays. This workflow emphasizes dose and time optimization, receptor-aware experimental design, and troubleshooting across AML, hepatocellular carcinoma, and liver-disease models.
-
Reversine: Turning Mitotic Stress into Translational Insight
2026-08-28
A mechanistic and strategic guide to using Reversine as an Aurora kinase inhibitor for mitotic biology, cancer cell proliferation inhibition, and translational model development.
-
CD28–ARS2–PKM Splicing in CD8+ T Cells
2026-08-28
The reference study identifies a CD28–ARS2 signaling axis that remodels alternative splicing of PKM and gives activated CD8+ T cells greater flexibility in glucose catabolism. Its findings connect costimulatory signaling to metabolic and antitumor function while suggesting an experimental framework for separating glycolytic, TCA-cycle, and oxidative-stress readouts.
-
EPI-001 Workflow for AR N-Terminal Domain Studies
2026-08-27
EPI-001 enables direct interrogation of full-length and splice-variant androgen receptor signaling in prostate cancer and selected triple-negative breast cancer models. This practical workflow connects compound handling with cell-growth, migration, EMT, and transcriptional readouts while addressing solubility, controls, and interpretation risks.
-
Aprotinin for Protease-Controlled RBC Assays
2026-08-27
Aprotinin provides reversible serine protease control for blood, inflammation, and red blood cell membrane workflows. This guide shows how to use BPTI as a preanalytical protection tool while separating proteolytic effects from intrinsic membrane mechanics.
-
Cap1 Cas9 mRNA and the Precision Window
2026-08-26
Precision genome editing depends not only on guide design and nuclease fidelity, but also on how cells process, translate, and clear Cas9 mRNA. This thought-leadership article connects Cap1 architecture, m1Ψ modification, poly(A)-tail biology, and nuclear export control to practical translational strategy. It positions EZ Cap™ Cas9 mRNA (m1Ψ) as a research-ready platform for designing more interpretable genome-editing experiments in mammalian cells.
-
EZ Cap™ Human PTEN mRNA: Assay Design Guide
2026-08-26
Discover how EZ Cap™ Human PTEN mRNA (ψUTP) can function as a controlled gain-of-function tool for studying PTEN biology, PI3K/Akt signaling, and therapeutic resistance. This assay-centered guide connects molecular design, nanoparticle delivery, and rigorous cancer research decisions.